title: Can boosted atazanavir induce hyperlipotrophy?
abstract: Individual variations in glucuronation may result in differences in serum concentrations of atazanavir, resulting in lipodystrophy, illustrating the difficulty in adjusting dosage. We report the case of an HIV/HCV co-infected patient treated with atazanavir.
authors.affiliation: Infectious Diseases Department, Nice University Hospital, Nice Cedex 3, France. infectiologie@chu-nice.fr
authors.forename: P
authors.initials: P
authors.lastname: Dellamonica
mesh_terms: D000368:Aged; D000069446:Atazanavir Sulfate; D001663:Bilirubin / Q000097:blood; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced*; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D009842:Oligopeptides / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use
chemical_list: D009842:Oligopeptides; D011480:Protease Inhibitors; D011725:Pyridines; D000069446:Atazanavir Sulfate; D001663:Bilirubin